Do newer forms of radiation treatments surpass standard radiation in prostate cancer?
Several new types of radiation treatments are being introduced in the clinic for the treatment of prostate cancer and many are seeing increased adoption. However, data to confirm that the new treatments surpass standard radiation remain.
Individuals diagnosed with low-grade prostate cancer that is localized to the prostate gland are often offered radiation treatment, as are patients with localized metastases, in combination with hormone therapy. Radiation is also used in patients with relapsed disease or advanced disease. External beam radiation therapy (EBRT) and brachytherapy (internal radiation) are the 2 main types of radiation used in prostate cancer, according to the American Cancer Society. Newer EBRT treatments have been developed that are more precise and avoid exposure to healthy tissue: 3-dimensional conformal radiation therapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton beam radiation therapy.
A review of the Surveillance, Epidemiology, and End Results (SEER)-Medicare database identified an uptick in the adoption rates of IMRT and SBRT following their introduction in the clinic, although demographic differences were identified. Between 2001 and 2005, 5680 men (21%) received IMRT compared with standard radiation (n = 21,555). Men who received IMRT were older, had higher-grade tumors, and lived in more populated areas (P <.05). Between 2007 and 2011, 595 men (2%) received SBRT compared with standard radiation (n = 28,255)—these men were white, had lower-grade tumors, lived in more populated areas, and were more likely to live in the Northeast (P <.05). In their discussion, the authors indicated that local coverage determinations by Medicare administrative contractors also had a role to play in the adoption of SBRT and IMRT.
However, are these newer forms of radiation treatment better than standard radiation? The question will be answered by a trial being conducted at Case Comprehensive Cancer Center in Cleveland. The trial is designed to question the efficacy of SBRT (5 intense radiation treatments over 2 weeks) compared with standard radiation therapy (28 radiation treatments over 5.5 weeks). The results, though, aren’t expected to come in for another 8 years, mainly because prostate cancer is a very slow-growing tumor—this has given rise to the debate around active surveillance versus treatment for the disease.
Physician bias also weighs heavily on adoption of new treatments. If a physician refuses to enroll patients on a new drug or treatment, the trial would need to be shelved before it comes up to speed.
Finally, cost of the treatment is just another variable in this complicated equation of adopting a new treatment. A comparison of Medicare data for the period between 2004 and 2009 found that while the median cost of a course of radiation therapy for prostate cancer was $18,000, it could range from $11,300 to $25,500, depending on the practice type, geography, and individual radiation therapy provider.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More